Supplementary Figure 6: First iteration of REVEALER for the drug sensitivity to a MEK-inhibitor example.
From: Characterizing genomic alterations in cancer by complementary functional associations
A) The target is the MEK-inhibitor PD0325901 sensitivity profile and there is no seed feature (NULLSEED). REVEALER identifies BRAF mutation as the top hit. B) The clustered version of the same top scoring features shown in A.
